TY - JOUR
T1 - Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy
T2 - Literature review of management and prognostic factors
AU - Shahzad, Muhammad Asim
AU - Ishtiaq, Rizwan
AU - Zahid, Umar
AU - Anwer, Faiz
N1 - Publisher Copyright:
© 2016 BMJ Publishing Group Ltd.
PY - 2016
Y1 - 2016
N2 - Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential. Emerging biomarkers include carbonyl reductases (CBR1 and CBR3), aldo-keto reductases (AKR, type 1A1, 1C3, 7A2) and topoisomerase2β (Top2β). β blockers and ACE inhibitors have not only been shown to slow down the progression of cardiac dysfunction but also produce symptomatic improvement. Our case report describes a patient with acute myeloblastic leukaemia who developed severe cardiomyopathy acutely after starting the anthracycline-based regimen. Nevertheless, with timely intervention her symptoms improved and subsequently she successfully received allogeneic stem cell transplantation.
AB - Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential. Emerging biomarkers include carbonyl reductases (CBR1 and CBR3), aldo-keto reductases (AKR, type 1A1, 1C3, 7A2) and topoisomerase2β (Top2β). β blockers and ACE inhibitors have not only been shown to slow down the progression of cardiac dysfunction but also produce symptomatic improvement. Our case report describes a patient with acute myeloblastic leukaemia who developed severe cardiomyopathy acutely after starting the anthracycline-based regimen. Nevertheless, with timely intervention her symptoms improved and subsequently she successfully received allogeneic stem cell transplantation.
UR - http://www.scopus.com/inward/record.url?scp=84996489163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996489163&partnerID=8YFLogxK
U2 - 10.1136/bcr-2016-217210
DO - 10.1136/bcr-2016-217210
M3 - Review article
C2 - 27852680
AN - SCOPUS:84996489163
SN - 1757-790X
VL - 2016
JO - BMJ case reports
JF - BMJ case reports
M1 - 217210
ER -